General
Prince of Songkla University Reports High Success Rate with CAR-T Cell Cancer Therapy
The Faculty of Medicine at Prince of Songkla University has announced a 90% remission rate in patients treated with their locally developed PSU CAR-T cell therapy.
On August 4, 2026, the Faculty of Medicine at Prince of Songkla University (PSU) reported significant progress in its cancer treatment program. According to Assistant Professor Dr. Nalinee Kovitvanavong, the university has successfully utilized CAR-T cell therapy to treat patients suffering from lymphoma, leukemia, and systemic lupus erythematosus (SLE). Clinical results indicate that nearly 90% of these patients have achieved complete remission.
Associate Professor Dr. Jakkrawadee Julamanee, Director of the Center of Excellence for Stem Cell Transplantation and Cellular Therapy, noted that the development of the 'PSU CAR-T Cell' innovation aims to reduce the high costs associated with importing similar medical products from abroad. The university is currently working to establish a dedicated production facility, with the goal of treating more than 100 cancer patients annually.
For residents and long-term visitors in Thailand, this development represents a notable advancement in domestic medical capabilities, potentially increasing access to advanced cellular therapies within the country. While these results are promising, the long-term scalability of the production facility and the specific criteria for patient eligibility remain to be confirmed as the university moves toward its goal of expanded annual treatment capacity. This report is based on information provided by Khaosod Online Thailand.
Translated from Thai.
SawaLife is not a news organisation. We classify and translate source material using automated processing and editorial controls; the original publication remains the authoritative context.